Insulin pump therapy in youth with type 1 diabetes: Toward closed-loop systems

Expert Opinion on Drug Delivery

Volumn 11, Issue 6, 2014, Pages 943-955

  Tauschmann, Martin ^a,b   Hovorka, Roman ^a,b  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bolus calculator; Bolus profile; Closed loop insulin delivery; Continuous glucose monitor; Control algorithm; Diabetes; Euglycemia; Insulin pump; Sensor augmented pump therapy; Smart pump; Suspend

Indexed keywords

INSULIN;

ALGORITHM; BLOOD GLUCOSE MONITORING; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLOSED LOOP SYSTEM; CONTINUOUS GLUCOSE MONITORING; DRUG DELIVERY DEVICE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; OUTCOME ASSESSMENT; PATIENT SAFETY; QUALITY OF LIFE; REVIEW; SENSOR AUGMENTED INSULIN PUMP; SMART PUMP; SOCIAL PSYCHOLOGY; THRESHOLD SUSPEND INSULIN PUMP;

BOLUS CALCULATOR; BOLUS PROFILE; CLOSED-LOOP INSULIN DELIVERY; CONTINUOUS GLUCOSE MONITOR; CONTROL ALGORITHM; DIABETES; EUGLYCEMIA; INSULIN PUMP; SENSOR-AUGMENTED PUMP THERAPY; SMART PUMP; SUSPEND;

ADOLESCENT; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 84901259795     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.910192     Document Type: Review

References (112)

1. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002;51(12):3353-61
2. Group DP. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23(8):857-66
3. Patterson CC, Gyurus E, Rosenbauer J, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: Evidence of non-uniformity over time in rates of increase. Diabetologia 2012;55(8):2142-7
4. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 2004;164(17):1917-24 (Pubitemid 39274363
5. Group DCCT. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86
6. Cryer PE. The barrier of hypoglycemia in Diabetes. Diabetes 2008;57(12):3169-76
7. Davis EA, Keating B, Byrne GC, et al. Hypoglycemia: Incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997;20(1):22-5 (Pubitemid 27020036
8. Kaufman FR, Epport K, Engilman R, et al. Neurocognitive functioning in children Diagnosed with diabetes before age 10 years. J Diabetes Complications 1999;13(1):31-8 (Pubitemid 29195644
9. Barnard K, Thomas S, Royle P, et al. Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review. BMC Pediatr 2010;10:50
10. Johnson SR, Cooper MN, Davis EA, et al. Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents. Diabet Med 2013;30(9):1126-31
11. Barnea-Goraly N, Raman M, Mazaika P, et al. Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014;37(2):332-40
12. Gaudieri PA, Chen R, Greer TF, et al. Cognitive function in children with type 1 diabetes: A meta-Analysis. Diabetes Care 2008;31(9):1892-7
13. Group DCCT. Effect of intensive diabetes treatment on the development and progression of long-Term complications in adolescents with insulindependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994;125(2):177-88
14. Acerini CL, Williams RM, Dunger DB. Metabolic impact of puberty on the course of type 1 diabetes. Diabetes Metab 2001;27(4 Pt 2):S19-25
15. Hovorka R. Closed-loop insulin Delivery: From bench to clinical practice. Nat Rev Endocrinol 2011;7(7):385-95
16. Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300(11):573-8 (Pubitemid 9123116
17. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012;366(17):1616-24
18. Maahs DM, Horton LA, Chase HP. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010;12(Suppl 1):S59-65
19. Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: A follow-up report. Pediatrics 2004;114(6):1601-5 (Pubitemid 41754924
20. Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010(1):Cd005103
21. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: Meta-Analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25(7):765-74
22. Bangstad HJ, Danne T, Deeb L, et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009;10(Suppl 12):82-99
23. Muller-Godeffroy E, Treichel S, Wagner VM. Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus-A large-scale multicentre pilot study. Diabet Med 2009;26(5):493-501
24. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27(7):1554-8 (Pubitemid 38857425
25. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: A randomized open crossover trial. Pediatrics 2003;112(3 Pt 1):559-64 (Pubitemid 37082107
26. Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and costeffectiveness of continuous subcutaneous insulin infusion for diabetes: Systematic review and economic evaluation. Health Technol Assess 2010;14(11):iii-v; xi-xvi, 1-181
27. Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: A systematic review and meta-Analysis of randomized control trials. Pediatr Diabetes 2009;10(1):52-8
28. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin Delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-Analysis. Ann Intern Med 2012;157(5):336-47
29. Kordonouri O, Hartmann R, Lauterborn R, et al. Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients: One-year follow-up comparison by matched-pair analysis. Diabetes Care 2006;29(1):133-4 (Pubitemid 44033444
30. Johnson SR, Cooper MN, Jones TW, et al. Long-Term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 2013;56(11):2392-400
31. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: Still the best option for insulin therapy. Diabetes Metab Res Rev 2009;25(2):99-111
32. Heinemann L, Krinelke L. Insulin infusion set: The Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012;6(4):954-64
33. Heinemann L. Insulin pump therapy: What is the evidence for using different types of boluses for coverage of prandial insulin requirements?. J Diabetes Sci Technol 2009;3(6):1490-500
34. Jones SM, Quarry JL, Caldwell-McMillan M, et al. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther 2005;7(2):233-40 (Pubitemid 40586366
35. O'Connell MA, Gilbertson HR, Donath SM, et al. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: Impact of glycemic index and prandial bolus type. Diabetes Care 2008;31(8):1491-5
36. Ahola AJ, Makimattila S, Saraheimo M, et al. Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately. J Diabetes 2010;2(3):194-202
37. Ziegler R, Cavan DA, Cranston I, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: First results from the ABACUS trial. Diabetes Care 2013;36(11):3613-19
38. Rabbone I, Scaramuzza AE, Ignaccolo MG, et al. Carbohydrate counting with an automated bolus calculator helps to improve glycaemic control in children with type 1 diabetes using multiple daily injection therapy: An 18-month observational study. Diabetes Res Clin Pract 2014, doi:10.1016/j.diabres.2013. 12.026
39. Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- And postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008;25(9):1036-42
40. Enander R, Gundevall C, Stromgren A, et al. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes 2012;13(7):545-51
41. Ramotowska A, Szypowska A. Bolus calculator and wirelessly communicated blood glucose meter effectively reduce hypoglycemia in type 1 diabetic children - randomized controlled trial. Diabetes Metab Res Rev 2014;30(2):146-53
42. Heller A, Feldman B. Electrochemical glucose sensors and their applications in Diabetes management. Chem Rev 2008;108(7):2482-505
43. Oliver NS, Toumazou C, Cass AE, et al. Glucose sensors: A review of current and emerging technology. Diabet Med 2009;26(3):197-210
44. Damiano ER, El-Khatib FH, Zheng H, et al. A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 2013;36(2):251-9
45. Christiansen M, Bailey T, Watkins E, et al. A new-generation continuous glucose monitoring system: Improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther 2013;15(10):881-8
46. Keenan DB, Mastrototaro JJ, Zisser H, et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol Ther 2012;14(3):225-31
47. Weinzimer SA, Beck RW, Chase HP, et al. Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther 2005;7(5):675-80; discussion 81-3
48. Mauras N, Fox L, Englert K, et al. Continuous glucose monitoring in type 1 diabetes. Endocrine 2013;43(1):41-50
49. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Metaanalysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805
50. Langendam M, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012(1):Cd008101
51. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359(14):1464-76
52. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34(4):795-800
53. Mauras N, Beck R, Xing D, et al. A randomized clinical trial to assess the efficacy and safety of real-Time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care 2012;35(2):204-10
54. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-Augmented insulin pump therapy: Results of the first randomized treat-To-Target study. Diabetes Technol Ther 2008;10(5):377-83
55. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The RealTrend study. Diabetes Care 2009;32(12):2245-50
56. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-Augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012;13(1):6-11
57. Kordonouri O, Pankowska E, Rami B, et al. Sensor-Augmented pump therapy from the diagnosis of childhood type 1 diabetes: Results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010;53(12):2487-95
58. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: A randomised controlled trial. Diabetologia 2012;55(12):3155-62
59. Kordonouri O, Hartmann R, Pankowska E, et al. Sensor augmented pump therapy from onset of type 1 diabetes: Late follow-up results of the Pediatric Onset Study. Pediatr Diabetes 2012;13(7):515-18
60. Buckingham B, Beck RW, Ruedy KJ, et al. Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care 2013;36(12):4030-5
61. Matyka KA. Sweet dreams?.-nocturnal hypoglycemia in children with type 1 diabetes. Pediatr Diabetes 2002;3(2):74-81
62. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011;34(9):2023-5
63. Danne T, Kordonouri O, Holder M, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-Augmented pump therapy. Diabetes Technol Ther 2011;13(11):1129-34
64. Garg S, Brazg RL, Bailey TS, et al. Reduction in Duration of hypoglycemia by automatic suspension of insulin Delivery: The in-clinic ASPIRE study. Diabetes Technol Ther 2012;14(3):205-9
65. Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-Augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: A randomized clinical trial. JAMA 2013;310(12):1240-7
66. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369(3):224-32
67. Ly TT, Nicholas JA, Retterath A, et al. Analysis of glucose responses to automated insulin suspension with sensor-Augmented pump therapy. Diabetes Care 2012;35(7):1462-5
68. Guerci B, Meyer L, Salle A, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999;84(8):2673-8 (Pubitemid 30641991
69. Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010;33(5):1013-17
70. Buckingham BA, Cameron F, Calhoun P, et al. Outpatient safety assessment of an in-home predictive lowglucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther 2013;15(8):622-7
71. Danne T, Tsioli C, Kordonouri O, et al. The PILGRIM study: In silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther 2014. [Epub ahead of print]
72. Elleri D, Allen JM, Nodale M, et al. Suspended insulin infusion During overnight closed-loop glucose control in children and adolescents with Type 1 diabetes. Diabet Med 2010;27(4):480-4
73. Kadish AH. Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. Am J Med Electron 1964;3:82-6
74. Renard E, Costalat G, Chevassus H, et al. Artificial beta-cell: Clinical experience toward an implantable closedloop insulin Delivery system. Diabetes Metab 2006;32(5 Pt 2):497-502 (Pubitemid 44836980
75. Steil GM, Rebrin K, Darwin C, et al. Feasibility of automating insulin Delivery for the treatment of type 1 diabetes. Diabetes 2006;55(12):3344-50 (Pubitemid 44923591
76. Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin Delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31(5):934-9
77. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin Delivery in children and adolescents with type 1 diabetes: A phase 2 randomised crossover trial. Lancet 2010;375(9716):743-51
78. Atlas E, Nimri R, Miller S, et al. MD-logic artificial pancreas system: A pilot study in adults with type 1 diabetes. Diabetes Care 2010;33(5):1072-6
79. El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2(27):27ra27
80. Group DCCT. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90(4):450-9
81. Marzelli MJ, Mazaika PK, Barnea-Goraly N, et al. Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes 2014;63(1):343-53
82. Elleri D, Acerini CL, Allen JM, et al. Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol Ther 2010;12(1):35-9
83. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: Past, present, future. Diabetes 2011;60(11):2672-82
84. O'Grady MJ, Retterath AJ, Keenan DB, et al. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35(11):2182-7
85. Sherr JL, Cengiz E, Palerm CC, et al. Reduced hypoglycemia and increased time in target using closed-loop insulin Delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes Care 2013;36(10):2909-14
86. Nimri R, Danne T, Kordonouri O, et al. The 'Glucositter' overnight automated closed loop system for type 1 diabetes: A randomized crossover trial. Pediatr Diabetes 2013;14(3):159-67
87. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin Delivery over 36 hours in adolescents with type 1 diabetes: Randomized clinical trial. Diabetes Care 2013;36(4):838-44
88. Buckingham BA, Beck RW, Ruedy KJ, et al. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 2013;15(5):401-8
89. Dauber A, Corcia L, Safer J, et al. Closed-loop insulin therapy improves glycemic control in children aged 7 years: A randomized controlled trial. Diabetes Care 2013;36(2):222-7
90. Renard E, Cobelli C, Kovatchev BP. Closed loop developments to improve glucose control at home. Diabetes Res Clin Pract 2013;102(2):79-85
91. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368(9):824-33
92. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: First studies of wearable artificial pancreas. Diabetes Care 2013;36(7):1851-8
93. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: A single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014;15(2):91-9
94. Hovorka R, Elleri D, Thabit H, et al. Overnight closed loop insulin Delivery in young people with type 1 diabetes: A free-living randomised clinical trial. Diabetes Care 2014, doi 10.2337/DC13-644
95. Bakhtiani PA, Zhao LM, El Youssef J, et al. A review of artificial pancreas technologies with an emphasis on bihormonal therapy. Diabetes Obes Metab 2013;15(12):1065-70
96. Pickup JC. Management of diabetes mellitus: Is the pump mightier than the pen?. Nat Rev Endocrinol 2012;8(7):425-33
97. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002;19(9):746-51 (Pubitemid 35013853
98. Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001;24(11):1923-8 (Pubitemid 33716502
99. Hofer SE, Heidtmann B, Raile K, et al. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPN Database in Germany and Austria. Pediatr Diabetes 2010;11(2):116-21
100. Tansey M, Laffel L, Cheng J, et al. Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. Diabet Med 2011;28(9):1118-22
101. Beck RW, Lawrence JM, Laffel L, et al. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care 2010;33(10):2175-7
102. Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32(8):1378-83
103. Hirose M, Beverly EA, Weinger K. Quality of life and technology: Impact on children and families with diabetes. Curr Diab Rep 2012;12(6):711-20
104. Peyrot M, Rubin RR, Group SS. Treatment satisfaction in the sensor-Augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabet Med 2013;30(4):464-7
105. Rubin RR, Peyrot M, Group SS. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012;14(2):143-51
106. Castle JR, Pitts A, Hanavan K, et al. The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes. Diabetes Care 2012;35(4):706-10
107. Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24(11):1858-62 (Pubitemid 33716491
108. Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008;31(1):44-6
109. Cengiz E, Weinzimer SA, Sherr JL, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabetes 2013;14(3):168-73
110. Hompesch M, Muchmore DB, Morrow L, et al. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011;34(3):666-8
111. Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35(10):1994-9
112. Regittnig W, Lindpointner S, Korsatko S, et al. Periodic extraction of interstitial fluid from the site of subcutaneous insulin infusion for the measurement of glucose: A novel single-port technique for the treatment of type 1 diabetes patients. Diabetes Technol Ther 2013;15(1):50-9